KURA NASDAQ
Kura Oncology, Inc.
1W: -5.0%
1M: -2.0%
3M: +9.6%
YTD: -1.8%
1Y: +56.9%
3Y: -7.8%
5Y: -44.5%
$9.31
-0.84 (-8.28%)
Weekly Expected Move ±7.4%
$9
$10
$10
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$826.5M
52W Range5.45-12.49
Volume1,443,894
Avg Volume1,728,409
Beta0.35
Dividend—
Analyst Ratings
Company Info
CEOTroy Wilson
Employees260
SectorHealthcare
IndustryBiotechnology
IPO Date2015-09-16
Websitekuraoncology.com
4930 Directors Place
San Diego, CA 92121
US
San Diego, CA 92121
US
858 500 8800
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest News
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology, Inc. Q1 2026 Earnings Call Summary
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Leoni Mollie | S-Sale | 84,929 | $9.82 | 2026-06-18 |
| Parks Diane L. | A-Award | 35,000 | $8.77 | 2026-06-04 |
| VASCONCELLES MICHAEL | A-Award | 35,000 | $8.77 | 2026-06-04 |
| Hasnain Faheem | A-Award | 35,000 | $8.77 | 2026-06-04 |
| Collins Helen Louise | A-Award | 35,000 | $8.77 | 2026-06-04 |